Search Results - "Metzger O"

Aerial tramways in the metal-mining industry.

Authors: Metzger, O. H.

Source: United States Bureau of Mines. Information Circular; 1940, Vol. 7095, p1-47, 47p

Reconnaissance of placer-mining districts in Lemhi county, Idaho.

Authors: Lorain, S. H. Metzger, O. H.

Source: United States Bureau of Mines. Information Circular; 1939, Vol. 7082, p1-81, 81p

Reconnaissance of placer mining in Boise county, Idaho.

Authors: Metzger, O. H.

Source: United States Bureau of Mines. Information Circular; 1938, Vol. 7028, p1-34, 34p

Reconnaissance of placer mining districts in Idaho county, Idaho.

Authors: Lorain, S. H. Metzger, O. H.

Source: United States Bureau of Mines. Information Circular; 1938, Vol. 7023, p1-93, 93p

Gold mining and milling in the Wickenburg area, Maricopa and Yavapai counties, Ariz.

Authors: Metzger, O. H.

Source: United States Bureau of Mines. Information Circular; 1938, Vol. 6991, p1-78, 78p

Gold mining in New Mexico.

Authors: Metzger, O. H.

Source: United States Bureau of Mines. Information Circular; 1938, Vol. 6987, p1-71, 71p

Aerial tramways in the metal mining industry.

Authors: Metzger, O. H.

Source: United States Bureau of Mines. Information Circular; 1937, Vol. 6948, p1-32, 32p

42O Biomarker analysis from KAITLIN, a randomised phase III study of adjuvant trastuzumab emtansine (TDM-1; K) plus pertuzumab (P) versus trastuzumab (H) plus taxane (T) plus P after anthracyclines (AC) for high-risk HER2-positive early breast cancer (EBC)

Authors: Metzger, O. Lambertini, C. Krop, I.E. et al.

Source: Annals of Oncology. 2021 Supplement 2, Vol. 32, pS37-S38. 2p.

6 Oral - Clinical utility of MammaPrint testing in Invasive Lobular Carcinoma: Results from the MINDACT phase III trial.

Authors: Metzger, O. Cardoso, F. Poncet, C. et al.

Source: European Journal of Cancer. 2020 Supplement 1, Vol. 138, pS5-S6. 2p.

Aerial tramways in the metal mining industry.

Authors: Metzger, O. H.

Source: Engineering & Mining Journal (00958948); February 1939, Vol. 140, p149-150, 2p

Aerial tramways in the metal mining industry.

Authors: Metzger, O. H.

Source: Engineering & Mining Journal (00958948); December 1938, Vol. 139, p109-110, 2p

369TiPPATINA: A randomized, open label, phase III trial to evaluate the efficacy and safety of palbociclib + Anti-HER2 therapy + endocrine therapy (ET) vs. anti-HER2 therapy + ET after induction treatment for hormone receptor positive (HR+)/HER2-positive metastatic breast cancer (MBC)

Authors: Loibl, S Metzger, O Mandrekar, S J et al.

Source: Annals of Oncology. 2018 Supplement, Vol. 29, pN.PAG-N.PAG. 1p.

Characterization of PIK3CA mutations in lobular breast cancer.

Authors: Desmedt, C. Metzger, O. Fumagalli, D. et al.

Source: Cancer Research. Dec2012 Meeting Abstracts, Vol. 72 Issue 24a, p857-858. 2p.

Relative effectiveness of letrozole compared with tamoxifen for patients with lobular carcinoma in the BIG 1-98 trial.

Authors: Metzger, O. Giobbie-Hurder, A. Mallon, E. et al.

Source: Cancer Research. Dec2012 Meeting Abstracts, Vol. 72 Issue 24a, p2161-2161. 1p.

Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial.

Authors: Geyer, C.E. Sikov, W.M. Huober, J. et al.

Source: Annals of Oncology. Apr2022, Vol. 33 Issue 4, p384-394. 11p.

485MO Health-related quality of life (HRQoL) from the PATINA trial (AFT-38): Impact of adding palbociclib to HER2 and endocrine therapy (ET) after induction in HR+/HER2+ metastatic breast cancer (MBC).

Authors: Vaz-Luis, I.V. Mazza, G. Gligorov, J. et al.

Source: Annals of Oncology. 2025 Supplement 2, Vol. 36, pS401-S401. 1p.

246P Axillary management and outcomes after neoadjuvant endocrine therapy in the randomized PELOPS trial.

Authors: Weiss, A.C. Jin, Q. Tayob, N. et al.

Source: Annals of Oncology. 2024 Supplement 2, Vol. 35, pS318-S318. 1p.

1LBA LBA Oral - Adjuvant chemotherapy with or without atezolizumab for stage II and III triple-negative breast cancer: final analysis of the ALEXANDRA/ IMpassion030 phase 3 trial.

Authors: McArthur, H. Bailey, A. Saji, S. et al.

Source: European Journal of Cancer. Mar2024:Supplement 1, Vol. 200, pN.PAG-N.PAG. 1p.

119O Event-free survival (EFS), overall survival (OS), and safety of adding veliparib (V) plus carboplatin (Cb) or carboplatin alone to neoadjuvant chemotherapy in triple-negative breast cancer (TNBC) after ≥4 years of follow-up: BrighTNess, a randomized phase III trial

Authors: Loibl, S. Sikov, W. Huober, J. et al.

Source: Annals of Oncology. 2021 Supplement 5, Vol. 32, pS408-S408. 1p.

LBA12 PALLAS: A randomized phase III trial of adjuvant palbociclib with endocrine therapy versus endocrine therapy alone for HR+/HER2- early breast cancer.

Authors: Mayer, E.L. Gnant, M.I. DeMichele, A. et al.

Source: Annals of Oncology. 2020 Supplement 4, Vol. 31, pS1145-S1145. 1p.